Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. [electronic resource]
Producer: 20081031Description: 920-6 p. digitalISSN:- 1523-6536
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Busulfan -- therapeutic use
- Female
- Graft Survival
- Graft vs Host Disease -- drug therapy
- Hematologic Neoplasms -- complications
- Histocompatibility Testing
- Humans
- Immunosuppressive Agents -- administration & dosage
- Male
- Methotrexate -- administration & dosage
- Middle Aged
- Peripheral Blood Stem Cell Transplantation -- adverse effects
- Premedication
- Sirolimus -- administration & dosage
- Tacrolimus -- administration & dosage
- Tissue Donors
- Transplantation Conditioning -- methods
- Transplantation, Homologous
- Vidarabine -- analogs & derivatives
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.